Early detection of disease progression is the best (and often the only) opportunity for curative cancer therapy.
  • Effective monitoring of disease progression requires tumor profile data which are not optimally available at present:
    • Tissue biopsy

    • Invasive and often yields insufficient tumor sample volume

    • Only indicative of primary tumor status (cancer is highly heterogeneous)

  • Blood sample based testing - liquid biopsy
    • In vitro (blood sample) approach provides insufficient blood volume to achieve required sensitivity and analytical validity

HaimaChek's in vivo liquid biopsy approach addresses limitations of biopsy and blood sample based approaches
  • Majority of pharmaceutical innovation in oncology is focused on targeted therapy but lack of patient profiling and companion diagnostic technologies is driving highly ineffective treatment selections:
    • Difficulty in selecting likely responder patients

    • Trial and error approach with highly toxic and expensive treatments

  • Clinical outcomes are significantly constrained

  • Due to the limitations of tissue biopsy and blood sample based testing both are currently unable to identity likely responders

  • PD-1/PD-L1, Third Generation TKIs, CAR-T, etc

An effective solution has remained elusive and represents a major unmet need. HaimaChek's BMProbe provides such a solution

The Approach - CTC Capture

Circulating Tumor Cells (CTCs)

Proven diagnostic and prognostic indicators of cancer progression
  • Individual cancer cells in peripheral blood

  • Shed from primary tumor mass very early in tumor development

  • Travel to anatomically distant sites via the blood stream

  • Are the mechanism of metastatic spread and important cause of cancer mortality

  • Exist in very low concentrations and cannot be reliably detected by existing diagnostic assays (typical 10 mL blood draw)

Early detection of CTCs would allow physicians to identify and treat patients at the beginning of metastatic spread